Progyny, Inc. Announces Third Quarter 2026 Results
Progyny reported record Q3 2026 revenue of $341.3 million, up 8.9% YoY, with net income of $26.3 million ($0.32 diluted EPS) nearly double the prior year's $13.9 million ($0.15). Gross margin expanded to 24.5% from 23.2%, and Adjusted EBITDA rose 6.3% to $58.4 million. The recent selling season delivered a record 1.3 million new covered lives and over 85 new clients, with near-100% retention into 2027. Management raised the midpoint of full-year guidance: FY26 revenue of $1.365B-$1.385B and Adjusted EBITDA of $235M-$240M.
Key figures
- Eps
- 0.32
- Revenue
- 341254000
- Guidance
- FY26 revenue $1.365B-$1.385B (5.9%-7.5% growth); net income $107.0M-$110.6M or $1.30-$1.35 per diluted share; Adjusted EBITDA $235.0M-$240.0M; Adjusted EPS $2.09-$2.13. Q4: revenue $344.7M-$364.7M; net income $28.5M-$32.1M; Adjusted EBITDA $57.9M-$62.9M; Adjusted EPS $0.53-$0.58.
- Revenue Yoy
- 8.9%
- Art cycles
- 16723
- Net income
- 26252000
- New clients
- 85
- Adjusted eps
- 0.52
- Client count
- 607
- Gross margin
- 24.5%
- Gross profit
- 83740000
- Adjusted ebitda
- 58439000
- Average members
- 7176000
- New covered lives
- 1.3 million
- Share repurchase q3
- $82.7 million (nearly 3 million shares)
- Adjusted ebitda margin
- 17.1%
- Operating cash flow q3
- 56600000
- Cash and marketable securities
- 195600000
- Remaining buyback authorization
- $51 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.